Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2006;48:519-526
Published online before print September 4, 2006, doi: 10.1161/01.HYP.0000240331.32352.0c
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
48/4/519    most recent
01.HYP.0000240331.32352.0cv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giunti, S.
Right arrow Articles by Cooper, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giunti, S.
Right arrow Articles by Cooper, M. E.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Diabetic Kidney Problems
*High Blood Pressure
Related Collections
Right arrow Animal models of human disease
Right arrow Type 1 diabetes
Right arrow Type 2 diabetes

(Hypertension. 2006;48:519.)
© 2006 American Heart Association, Inc.


Brief Reviews

Mechanisms of Diabetic Nephropathy

Role of Hypertension

Sara Giunti; David Barit; Mark E. Cooper

From the Danielle Alberti Memorial Center for Diabetic Complications, Diabetes and Metabolism Division, Baker Heart Research Institute, Melbourne, Australia.

Correspondence to Mark Cooper, Baker Medical Research Institute, 75 Commercial Rd, Prahran VIC 3181, Melbourne, Australia. E-mail mark.cooper@baker.edu.au


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 


*    Introduction
 
Diabetic nephropathy is a major microvascular complication of diabetes, representing the leading cause of end-stage renal disease in the Western world, and a major cause of morbidity and mortality in both type 1 and type 2 diabetic subjects. Clinical hallmarks of diabetic nephropathy include a progressive increase in urinary albumin excretion and a decline in glomerular filtration rate (GFR), which occur in association with an increase in blood pressure, ultimately leading to end-stage renal failure.1 These renal functional changes develop as a consequence of structural abnormalities, including glomerular basement membrane thickening, mesangial expansion with extracellular matrix accumulation, changes in glomerular epithelial cells (podocytes), including a decrease in number and/or density, podocyte foot process broadening and effacement, glomerulosclerosis, and tubulointerstitial fibrosis.

Diabetic nephropathy occurs only in a minority of subjects with either type 1 or type 2 diabetes and seems to result from the interaction between genetic susceptibility and environmental insults, primarily metabolic and hemodynamic in origin. Over the last decade, the cellular and molecular mechanisms by which these insults translate to structural and functional abnormalities leading to diabetic nephropathy have been increasingly delineated. In particular, it has been determined that both metabolic and hemodynamic stimuli lead to the activation of key intracellular signaling pathways and transcription factors, thus triggering the production/release of cytokines, chemokines, and growth factors, which mediate and/or amplify renal damage.

In the present review, we summarize molecular and cellular mechanisms that seem to be responsible for hypertension-induced renal injury in diabetes, with particular focus on the role . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
Toxicol SciHome page
J.-S. Huang, L.-Y. Chuang, J.-Y. Guh, and Y.-J. Huang
Effects of Nitric Oxide and Antioxidants on Advanced Glycation End Products-Induced Hypertrophic Growth in Human Renal Tubular Cells
Toxicol. Sci., September 1, 2009; 111(1): 109 - 119.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
J. H. Garman, S. Mulroney, M. Manigrasso, E. Flynn, and C. Maric
Omega-3 fatty acid rich diet prevents diabetic renal disease
Am J Physiol Renal Physiol, February 1, 2009; 296(2): F306 - F316.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
P. D. B. Ribaldo, D. S. Souza, S. K. Biswas, K. Block, J. M. Lopes de Faria, and J. B. Lopes de Faria
Green tea (Camellia sinensis) Attenuates Nephropathy by Downregulating Nox4 NADPH Oxidase in Diabetic Spontaneously Hypertensive Rats
J. Nutr., January 1, 2009; 139(1): 96 - 100.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
Y. S. Kanwar, J. Wada, L. Sun, P. Xie, E. I. Wallner, S. Chen, S. Chugh, and F. R. Danesh
Diabetic Nephropathy: Mechanisms of Renal Disease Progression
Experimental Biology and Medicine, January 1, 2008; 233(1): 4 - 11.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
N. K. Sweitzer, M. Shenoy, J. H. Stein, S. Keles, M. Palta, T. LeCaire, and G. F. Mitchell
Increases in Central Aortic Impedance Precede Alterations in Arterial Stiffness Measures in Type 1 Diabetes
Diabetes Care, November 1, 2007; 30(11): 2886 - 2891.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
J.-S. Huang, L.-Y. Chuang, J.-Y. Guh, Y.-J. Huang, and M.-S. Hsu
Antioxidants attenuate high glucose-induced hypertrophic growth in renal tubular epithelial cells
Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1072 - F1082.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
Y. Kanetsuna, K. Takahashi, M. Nagata, M. A. Gannon, M. D. Breyer, R. C. Harris, and T. Takahashi
Deficiency of Endothelial Nitric-Oxide Synthase Confers Susceptibility to Diabetic Nephropathy in Nephropathy-Resistant Inbred Mice
Am. J. Pathol., May 1, 2007; 170(5): 1473 - 1484.
[Abstract] [Full Text] [PDF]